G-L

Sort by Default

Display 15 Products per page

Ipatasertib
Read More
Ipatasertib (Roche) is a highly selective, ATP-competitive Akt inhibitor that preferentially targets active, phosphorylated Akt.
February 26, 2020
Find out more
Lynparza
Read More
Lynparza (olaparib; AstraZeneca) is a small molecule poly (ADP-ribose) polymerase (PARP) inhibitor. The PARP enzyme plays a central role in a number of cellular processes involved in cellular homeostasis.
February 26, 2020
Find out more
Keytruda
Read More
Keytruda is a humanized monoclonal antibody designed to inhibit the PD-1 co-inhibitory receptor. The interaction between PD-1 and its primary ligand, PD-L1, inhibits T-cell proliferation and survival, and induces apoptosis of tumor-specific T-cells.
February 26, 2020
Find out more
Halaven
Read More
Halaven (eribulin mesylate; Eisai) is a synthetic macrocyclic ketone analog of halichondrin B that acts as a tubulin depolymerizer and functionally inhibits tumor cell proliferation with arrest in the G2-M phase of cell growth. B
February 26, 2020
Find out more
Juxtapid
Read More
Juxtapid (lomitapide mesylate) is a novel, first-in-class microsomal triglyceride transfer protein (MTP) inhibitor marketed by Aegerion.
November 20, 2019
Find out more
Inclisiran
Read More
Inclisiran (The Medicines Company/Alnylam Pharmaceuticals) is a systemically delivered siRNA therapeutic targeting mRNA for PCSK.
November 20, 2019
Find out more
Imfinzi
Read More
Imfinzi (durvalumab; AstraZeneca) is a human monoclonal antibody directed against programmed death-ligand 1 (PD-L1).
September 9, 2019
Find out more
Lenvima
Read More
Lenvima (lenvatinib; Eisai/Novartis/Merck & Co) is an orally available small molecule inhibitor of multiple tyrosine kinases including vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), and fibroblast growth factor receptor (FGFR).
September 9, 2019
Find out more
Juluca
Read More
Juluca ([dolutegravir + rilpivirine]; ViiV Healthcare/Johnson & Johnson) is a single-tablet regimen approved in the US for the treatment of patients infected with HIV-1 who have achieved viral suppression.
June 28, 2019
Find out more
leronlimab
Read More
Leronlimab (CytoDyn) is a humanized monoclonal antibody directed against C-C chemokine receptor 5 (CCR5), which is a co-receptor required for the attachment and entry of CCR5-tropic HIV-1 viruses into host cells.
June 28, 2019
Find out more
Isentress
Read More
Isentress (raltegravir; Merck & Co) is a twice-daily, unboosted integrase inhibitor (INI) that is used in combination with other antiretroviral drugs for treatment of HIV-1 infection.
June 28, 2019
Find out more
Genvoya
Read More
Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide fumarate [TAF]; Gilead) is a single-tablet regimen (STR) approved for the treatment of HIV-1 infection.
June 28, 2019
Find out more
Lexapro
Read More
Lexapro (escitalopram; Allergan/Lundbeck/Mitsubishi Tanabe/Mochida) is a selective serotonin reuptake inhibitor, and acts by blocking the re-uptake of serotonin.
March 29, 2019
Find out more
Latuda
Read More
Latuda (lurasidone; Sumitomo Dainippon/Angelini) contains the atypical antipsychotic lurasidone, which acts as an antagonist of dopamine receptors D2, and serotonin receptors 5-HT2A. By inhibiting the synaptic reuptake of dopamine and serotonin, Latuda helps to normalize brain activity and reduce schizophrenia symptoms.
March 29, 2019
Find out more
Inlyta
Read More
Inlyta (axitinib; Pfizer) is a kinase inhibitor designed to selectively inhibit vascular endothelial growth factor receptor-1.
March 6, 2019
Find out more

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726

Call Back

Name

Email *

Company name *

Phone number *